Similar articles

• The effect of tamoxifen and stilboestrol on plasma hormone levels in postmenopausal women with advanced breast cancer.

  McFadyen IJ, Raab G, Forrest AP, Langlands AO, Stewart HJ, Roberts MM, Hamilton T, Golder MP, Groom GV, Griffiths K. McFadyen IJ, et al. Clin Oncol. 1979 Sep;5(3):251-6. Clin Oncol. 1979. PMID: 387323 Clinical Trial. No abstract available.
• Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.

  Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Rorth M, Daehnfeldt JL, Rose C. Mouridsen HT, et al. Eur J Cancer (1965). 1980;Suppl 1:107-10. Eur J Cancer (1965). 1980. PMID: 7032918 Clinical Trial. No abstract available.
• CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.

  Mouridsen HT, Palshof T, Engelsman E, Sylvester R. Mouridsen HT, et al. Eur J Cancer (1965). 1980;Suppl 1:119-23. Eur J Cancer (1965). 1980. PMID: 7032921 Clinical Trial. No abstract available.
• Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

  Vogel VG. Vogel VG. Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916233 Review.
• Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.

  Berry J. Berry J. Clin Ther. 2005 Nov;27(11):1671-84. doi: 10.1016/j.clinthera.2005.11.013. Clin Ther. 2005. PMID: 16368441 Review.